Is Regeneron Pharmaceuticals, Inc. (REGN) a Buy, Sell, or Hold?
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$656.12 USD
-$6.97 (-1.05%)
- Volume
- 477.99K
- Average Volume
- 1.01M
- Market Capitalization
- $67.59B
- P/E Ratio
- 15.43
- Dividend Yield
- 0.55%
- Price Target
- $839.50
- Year High
- $821.11
- Year Low
- $541.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.08
- Current Ratio
- $3.57
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Leonard S. Schleifer |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | REGN |
| CUSIP | 75886F107 |
| CIK | 0000872589 |
| Web | https://www.regeneron.com |
| Phone | 914 847 7000 |
| Currency | USD |
| Employees | 15410 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.09 |
| Payout Ratio | 0.08 |
| Current Ratio | 3.57 |
| Quick Ratio | 2.96 |
| Cash Ratio | 0.58 |
Sales & Book Value
| Annual Sales | $14.34B |
| Price / Sales | 4.53 |
| Cash Flow | 39.95 |
| Price / Cash Flow | 16.27 |
| Price / Book | 2.17 |
Price Target and Rating
| Average Stock Price Forecast | $839.50 |
| High Stock Price Forecast | $995.00 |
| Low Stock Price Forecast | $641.00 |
| Forecast Upside/Downside | -21.84% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 49 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $41.48 |
| Trailing P/E Ratio | 15.43 |
| PEG Ratio | 8.37 |
| P/E Growth | 8.37 |
| Net Income | $4.5B |
| Net Margin | 29.65% |
| Pretax Margin | 34.56% |
| Return on Equity | 14.32% |
| Return on Assets | 10.82% |
Financials Score
| AltmanZ Score | 6.76 |
| Piotroski Score | 5.00 |
| Working Capital | 13.1B |
| Total Assets | 40.87B |
| Ebit | 5.2B |
| Market Cap | 68.31B |
| Total Liabilities | 9.45B |
Poll Results
About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heter ... ozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
2026-07-09 09:56:07
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
2026-07-07 13:11:07
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2026-07-07 12:30:17
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Here's Why Regeneron (REGN) is a Strong Value Stock
2026-07-07 10:41:13
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
2026-07-07 09:56:08
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term
2026-07-02 10:51:08
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
2026-07-01 15:45:00
It might pull it off, provided several things fall right in place.
2026-06-29 15:03:21
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday citing an FDA spokesperson.
Frequently Asked Questions
-
What is the current Regeneron Pharmaceuticals, Inc. (REGN) stock price?
-
Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN) stock price is $656.12 in the last trading session. During the trading session, REGN stock reached the peak price of $821.11 while $541 was the lowest point it dropped to. The percentage change in REGN stock occurred in the recent session was --1.05% while the dollar amount for the price change in REGN stock was -$-6.97.
-
REGN's industry and sector of operation?
-
The NASDAQ listed REGN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of REGN?
-
Christopher R. Fenimore | Executive Vice President of Finance & Chief Financial Officer
Ryan Steinberger | Executive VP, Chief Digital & Technology Officer
Melissa Lozner | Senior Vice President & Chief Compliance Officer
Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations
Leonard S. Schleifer | Co-Founder, President, Chief Executive Officer & Co-Chairman -
How many employees does REGN have?
-
Number of REGN employees currently stands at 15410. REGN operates from 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, US.
-
Link for REGN official website?
-
Official Website of REGN is: https://www.regeneron.com
-
How do I contact REGN?
-
REGN could be contacted at phone #914 847 7000 and can also be accessed through its website. REGN operates from 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, US.
-
How many shares of REGN are traded daily?
-
The average number of REGN shares traded daily for last 3 months was 1.01M.
-
What is the market cap of REGN currently?
-
The market value of REGN currently stands at $67.59B with its latest stock price at $656.12